Lung Cancer News and Research

Latest Lung Cancer News and Research

Researchers develop new way to personalize treatments for aggressive bladder cancer

Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.

14 Aug 2015

IASLC announces winners of Advocacy Travel Awards

The International Association for the Study of Lung Cancer announced today the recipients of the Advocacy Travel Awards. Five winners will receive funding to attend the 16th World Conference on Lung Cancer (WCLC) Sept. 6-9, 2015 at the Colorado Convention Center in Denver.

13 Aug 2015

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.

11 Aug 2015

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead academic centers participating in the National Cancer Institute's (NCI) MATCH (Molecular Analysis for Therapy Choice) Trial in the United States, set to begin in the next few weeks.

11 Aug 2015

WPI awarded NIH grant to explore ways to turn genetic tables against cancer

Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.

7 Aug 2015

Cancer survival in England remains lower compared to other countries with similar healthcare systems

Cancer survival in England remains lower than countries with similar healthcare systems, according to a new Cancer Research UK funded study published in the British Journal of Cancer today (Wednesday).

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.

4 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche today announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration, as a companion diagnostic test for AZD9291, an AstraZeneca investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation.

30 Jul 2015

Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine if the tumor is malignant is histologic analysis. A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.

30 Jul 2015

Patients undergoing surgery for lung cancer wait too long to receive treatment, skip vital diagnostic steps

Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic Surgery.

30 Jul 2015

New study reports creation of genetic porcine model of cancer

With many types of cancers, early detection offers the best hope for survival. However, research into new early-detection screenings, as well as possible interventional radiology and surgical treatments, has been hindered by the lack of a large animal model that would accurately reflect the types of cancers seen in human cells.

30 Jul 2015

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).

29 Jul 2015

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer.

29 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

ALCF to honor Fred R. Hirsch with 2015 Addario Lectureship Award for lung cancer research

The Bonnie J. Addario Lung Cancer Foundation will honor Fred R. Hirsch, M.D., Ph.D., with the 2015 Addario Lectureship Award for his continued leadership and expertise in lung cancer treatment and research. Dr. Hirsch, CEO of the International Association for the Study of Lung Cancer, will receive the award at the 16th International Lung Cancer Congress held on July 30 – August 1 in Huntington Beach, California.

25 Jul 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

Researchers develop new way to personalize treatments for aggressive bladder cancer

IASLC announces winners of Advocacy Travel Awards

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

WPI awarded NIH grant to explore ways to turn genetic tables against cancer

Cancer survival in England remains lower compared to other countries with similar healthcare systems

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

Patients undergoing surgery for lung cancer wait too long to receive treatment, skip vital diagnostic steps

New study reports creation of genetic porcine model of cancer

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

New tool combines drugs to target kinase dependency in cancer

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

ALCF to honor Fred R. Hirsch with 2015 Addario Lectureship Award for lung cancer research

The ultimate guide to lung research tools and protocols eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in